Compare BridgeBio Pharma Inc (BBIO) vs Fortinet Inc (FTNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Fortinet Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Fortinet Inc trades at $162.06 (market cap $120.48B). The key difference: Fortinet Inc is far larger — about 7.3× BridgeBio Pharma Inc's market cap. Which is the better fit depends on your goals.
| BBIO | FTNT | |
|---|---|---|
Market Cap | $16.61B | $120.48B |
Sector | Health | Technology |
52-Week High | $90.17 | $168.29 |
52-Week Low | $47.29 | $75.23 |
Enterprise Value | $18.16B | $116.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Fortinet (FTNT) trades at $159.64, down 0.29% on the day, with a bullish technical signal from moving averages and a consensus price target of $174.50. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.90 surpassing the $0.746 expectation. Revenue growth remains robust, climbing to $6.80 billion in 2025, while net income margins exceed 28%. Positive media coverage highlights strong AI-driven cybersecurity demand and platform expansion.
Outlook is favorable given earnings momentum and industry tailwinds, but high valuation ratios (P/E of 56.41) pose a risk if growth slows. Investor sentiment is supported by analyst buy ratings (42.65%) and institutional accumulation, though competitive pressures and macroeconomic volatility require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
